Thyroid Cancer Diagnostics

Thyroid Cancer Diagnostics Market Outlook

The global thyroid cancer diagnostics market is poised to reach approximately USD 7.5 billion by 2035, growing at a remarkable compound annual growth rate (CAGR) of 9.2% during the forecast period from 2025 to 2035. The increasing prevalence of thyroid cancer, driven by factors such as hormonal changes, genetic predispositions, and lifestyle choices, is propelling the demand for effective diagnostic procedures. Moreover, the rising awareness regarding the early detection of thyroid cancer and advancements in diagnostic technologies are significantly contributing to market growth. As the global healthcare landscape evolves, there is a growing emphasis on personalized medicine, which in turn is intensifying the need for precise and efficient diagnostic solutions. Consequently, the thyroid cancer diagnostics market is undergoing robust growth, marked by an influx of innovative testing methods and an expanding array of services aimed at improving patient outcomes.

Growth Factor of the Market

One of the primary growth factors for the thyroid cancer diagnostics market is the rising incidence of thyroid cancer globally, which has been particularly noticeable in recent years. According to the American Cancer Society, the number of new thyroid cancer cases is expected to increase annually, thus highlighting the need for enhanced diagnostic testing. Additionally, advancements in technology, such as molecular testing and enhanced imaging methods, are enabling more accurate and quicker diagnoses, which is vital in managing this form of cancer effectively. Another contributing factor is the growing healthcare expenditure and increasing investments in cancer research, allowing for the development of innovative diagnostic techniques. Public health initiatives aimed at promoting awareness regarding thyroid health and the importance of regular screenings are also creating additional momentum for the market. Lastly, the growing geriatric population, which is more susceptible to various types of cancers, including thyroid cancer, is further propelling the demand for effective diagnostic solutions.

Key Highlights of the Market

• The global thyroid cancer diagnostics market is expected to reach USD 7.5 billion by 2035.
• The market is projected to grow at a CAGR of 9.2% from 2025 to 2035.
• Rising prevalence of thyroid cancer is driving demand for diagnostic testing.
• Technological advancements are enhancing the accuracy and efficiency of diagnostics.
• Growing awareness and public health initiatives are promoting early detection and screening.

By Test Type

Biopsy:

Biopsy remains one of the most critical diagnostic techniques employed in the evaluation of thyroid cancer. It involves the extraction of a sample of tissue from the thyroid gland to be examined for cancerous cells. This method is particularly valuable because it provides definitive evidence regarding the presence or absence of malignancy, thus guiding treatment decisions. Advances in biopsy techniques, such as fine needle aspiration biopsy (FNAB), have significantly improved the accuracy of diagnosis while minimizing patient discomfort. The increasing adoption of minimally invasive biopsy techniques is driving growth in this segment as they reduce recovery time and hospital stays, making it a preferred choice among healthcare providers and patients alike. Furthermore, as the medical community continues to emphasize the importance of precise diagnostics, the biopsy segment is expected to witness sustained growth in the coming years.

Blood Tests:

Blood tests are increasingly being recognized for their role in the early detection and monitoring of thyroid cancer. These tests measure the levels of specific hormones and markers that can indicate the presence of thyroid cancer. The convenience and non-invasive nature of blood tests make them an attractive option for both patients and healthcare providers. Advances in technology have allowed for more sophisticated blood tests that can detect tumor markers with higher sensitivity and specificity. As awareness of the importance of early detection grows, the use of blood tests in thyroid cancer diagnostics is expected to rise, supported by ongoing research and validation efforts to enhance their utility in clinical practice. This growth is further fueled by the increased accessibility of blood testing services, making it easier for patients to undergo regular screenings.

Thyroid Ultrasound:

Thyroid ultrasound is a pivotal imaging technique in the diagnosis and management of thyroid cancer. It utilizes sound waves to create images of the thyroid gland, enabling healthcare providers to identify abnormalities such as nodules or cysts that may warrant further investigation. The non-invasive nature of ultrasound, coupled with its ability to provide real-time imaging, makes it a widely used tool in clinical practice. The increasing prevalence of thyroid nodules, which can lead to cancer, is driving the demand for thyroid ultrasound procedures. Moreover, advancements in ultrasound technology, including high-resolution imaging and elastography, have enhanced its diagnostic capabilities, leading to better patient outcomes. As a result, the thyroid ultrasound segment is projected to see significant growth as healthcare professionals incorporate this tool into their diagnostic arsenal.

Thyroid Scan:

Thyroid scans, which involve the use of radioactive isotopes to visualize the thyroid gland’s function and structure, are critical in the evaluation of thyroid disease. This imaging technique helps to assess the functionality of thyroid nodules, distinguishing between benign and malignant growths. The increasing prevalence of thyroid disorders, along with the rising utilization of nuclear medicine, is expected to bolster the growth of the thyroid scan segment. Furthermore, advancements in radiopharmaceuticals and imaging technologies are enhancing the accuracy and safety of thyroid scans, thereby increasing their adoption in clinical settings. As healthcare professionals continue to seek comprehensive diagnostic options, the thyroid scan segment is anticipated to expand significantly in the thyroid cancer diagnostics market.

Fine Needle Aspiration:

Fine needle aspiration (FNA) is a minimally invasive procedure widely used in the diagnosis of thyroid cancer. It involves the insertion of a thin needle into the thyroid nodule to extract cellular material for cytological examination. FNA is favored for its ability to provide quick results with minimal discomfort to the patient, making it an essential tool in the diagnostic process. The accuracy and effectiveness of FNA have been enhanced through the integration of ultrasound guidance, which allows for precise needle placement. As healthcare providers increasingly advocate for less invasive diagnostic methods, the adoption of fine needle aspiration techniques is expected to rise, contributing to the overall growth of the thyroid cancer diagnostics market.

By User

Hospitals:

Hospitals are the primary users of thyroid cancer diagnostic services, as they provide a comprehensive range of diagnostic and treatment options for patients. The availability of advanced diagnostic technologies and skilled healthcare professionals in hospitals allows for accurate detection and timely intervention in cases of thyroid cancer. Hospitals are increasingly adopting integrated diagnostic workflows that combine multiple testing modalities to enhance the accuracy of diagnoses and improve patient outcomes. The growing emphasis on early detection and personalized treatment plans is further driving the demand for thyroid cancer diagnostics within hospital settings. As hospitals continue to expand their oncology services, the segment is anticipated to witness significant growth, supported by ongoing investments in advanced diagnostic technologies.

Diagnostic Laboratories:

Diagnostic laboratories play a crucial role in the thyroid cancer diagnostics market by offering specialized testing services that aid in the accurate diagnosis of thyroid malignancies. These laboratories are equipped with advanced technologies and skilled technicians who perform various tests, including biopsy analyses and molecular testing, to provide reliable results. As the demand for precise diagnostic testing continues to rise, diagnostic laboratories are increasingly investing in state-of-the-art equipment and technologies to enhance their service offerings. Moreover, the growing trend of outsourcing diagnostic services by hospitals to specialized laboratories is further propelling the growth of this segment. As diagnostic laboratories continue to expand their capabilities and improve turnaround times, they are expected to play an integral role in the thyroid cancer diagnostics market.

Cancer Research Institutes:

Cancer research institutes are pivotal in advancing the field of thyroid cancer diagnostics by engaging in research and development of innovative diagnostic technologies. These institutions focus on exploring new testing methodologies, biomarkers, and imaging techniques to improve early detection and monitoring of thyroid cancer. Collaborations between research institutes and healthcare providers are becoming increasingly common, allowing for the translation of research findings into clinical practice. The ongoing research initiatives aimed at understanding the genetic and molecular underpinnings of thyroid cancer are expected to yield significant advancements in diagnostic accuracy, thereby driving growth in this segment. As funding for cancer research continues to increase, cancer research institutes will likely play an essential role in shaping the future of thyroid cancer diagnostics.

Clinics:

Clinics are increasingly becoming significant users of thyroid cancer diagnostic services, particularly in providing accessible and convenient testing options for patients. Many clinics are equipped to perform essential diagnostic tests, including blood tests and ultrasound evaluations, which enable early detection of thyroid abnormalities. The growing trend of outpatient care and preventive health initiatives is driving the demand for diagnostic services within clinics. Furthermore, as patients seek more localized healthcare options, clinics are expanding their service offerings to include comprehensive cancer screening programs, including those for thyroid cancer. This shift towards integrated care delivery models is expected to enhance the role of clinics in the thyroid cancer diagnostics market, particularly in reaching underserved populations.

By Technology

Imaging Tests:

Imaging tests play a vital role in the diagnosis and management of thyroid cancer by providing detailed visual assessments of the thyroid gland. Techniques such as ultrasound, CT scans, and MRI are utilized to detect abnormalities, assess the size and extent of tumors, and guide treatment decisions. The advancements in imaging technology, particularly in ultrasound and PET scans, have transformed the diagnostic landscape, allowing for earlier and more accurate detection of thyroid cancers. The shift towards high-resolution imaging techniques has improved the ability to differentiate between benign and malignant nodules, thereby enhancing patient management. As the demand for non-invasive diagnostic methods continues to rise, the imaging tests segment is expected to grow significantly, driven by ongoing technological enhancements and the need for accurate diagnostics.

Molecular Testing:

Molecular testing is emerging as a transformative technology in the thyroid cancer diagnostics market, particularly for its role in identifying genetic mutations and biomarkers associated with thyroid malignancies. This testing involves analyzing the genetic material of thyroid cells to provide insights into the potential aggressiveness of tumors and guide treatment decisions. The increasing understanding of the molecular basis of thyroid cancer has spurred the development of various molecular tests that can predict patient outcomes more accurately. As personalized medicine gains traction in oncology, the demand for molecular testing is expected to rise sharply, allowing for tailored treatment approaches based on individual patient profiles. Thus, the molecular testing segment stands to significantly contribute to the growth of the thyroid cancer diagnostics market.

Blood Tests:

Blood tests are increasingly recognized for their utility in thyroid cancer diagnostics, particularly in monitoring hormone levels and detecting tumor markers. These tests are often used as part of a comprehensive diagnostic approach to assess thyroid function and identify potential malignancies. The convenience and non-invasive nature of blood tests make them a preferred option for patients, leading to increased adoption in clinical settings. Advances in blood testing technologies have enabled the development of highly sensitive assays that can detect minute changes in biomarker levels, thus enhancing diagnostic accuracy. As awareness regarding the importance of regular screenings grows, the blood tests segment is anticipated to witness significant expansion, driven by ongoing innovation in testing methodologies.

By Age Group

Pediatric:

The pediatric segment of the thyroid cancer diagnostics market is gaining attention due to the unique challenges associated with diagnosing thyroid cancer in children. While thyroid cancer is relatively rare in the pediatric population, when it does occur, it can often present differently than in adults. Hence, specialized diagnostic approaches are necessary for accurate assessment. The growing emphasis on early detection and the need for age-appropriate diagnostic protocols are driving the expansion of this segment. Research initiatives focused on understanding the epidemiology and molecular characteristics of pediatric thyroid cancer are also paving the way for improved diagnostic strategies tailored specifically for younger patients. As healthcare providers focus on enhancing awareness and screening for thyroid disorders in children, this segment is expected to grow steadily.

Adult:

The adult age group accounts for the majority of thyroid cancer cases, making it a significant focus within the thyroid cancer diagnostics market. The prevalence of thyroid cancer is higher among adults, particularly women, due to various risk factors including age, genetics, and environmental exposures. As a result, there is a strong demand for effective diagnostic tools and procedures that can accurately identify and characterize thyroid malignancies. The rise in routine screenings and diagnostic imaging in the adult population is further driving growth in this segment. Additionally, increasing public awareness campaigns and educational initiatives about thyroid health are contributing to earlier detection and diagnosis among adults, making this segment a key driver of the overall market.

By Region

The North American thyroid cancer diagnostics market is the largest globally, driven by high healthcare expenditure, advanced medical technologies, and a strong emphasis on early detection and treatment. The U.S. accounts for a significant share of the market due to the increasing incidence of thyroid cancer and the presence of leading diagnostic laboratories and research institutes. As per recent statistics, North America is expected to grow at a CAGR of approximately 8.5% during the forecast period, supported by ongoing investments in cancer research and advancements in diagnostic technologies. The growing awareness regarding thyroid health and the importance of regular screenings further bolster the demand for diagnostic services within this region.

In Europe, the thyroid cancer diagnostics market is witnessing significant growth due to the rising prevalence of thyroid cancer and the increasing adoption of advanced diagnostic technologies. Countries such as Germany, France, and the UK are at the forefront of this growth, driven by robust healthcare infrastructures and increasing investments in oncology research. The European market is projected to grow at a CAGR of around 7.8% during the forecast period, fueled by the growing emphasis on personalized medicine and early detection initiatives. The integration of innovative diagnostic methodologies and enhanced healthcare access in various European nations are expected to contribute to the overall expansion of the market in the region.

Opportunities

The thyroid cancer diagnostics market is rife with opportunities, particularly in the realm of technological advancements. The continuous evolution of diagnostic technologies, including the development of artificial intelligence and machine learning algorithms designed to enhance imaging interpretation and risk stratification, presents a promising avenue for growth. These innovations have the potential to revolutionize the diagnostic process, improving accuracy and efficiency while reducing diagnostic errors. Alongside technology, the increasing collaboration between diagnostic laboratories and healthcare providers can lead to the establishment of more comprehensive screening programs that can capture patients at risk, thus fostering early detection of thyroid cancer. Market players who invest in research and development to enhance diagnostic capabilities and improve patient outcomes stand to gain a competitive edge in this rapidly evolving landscape.

Another significant opportunity lies in the rising awareness and screening initiatives led by various organizations and healthcare systems. As public health campaigns focus on increasing knowledge about thyroid disorders and the importance of regular screenings, there is a promising potential to expand the patient base seeking diagnostic services. Additionally, as the global population ages, the demand for effective diagnostic solutions will only increase, creating a favorable environment for market growth. Companies that position themselves strategically to capitalize on these trends—by developing targeted educational programs, improving access to diagnostic services, and enhancing patient engagement—will be well-placed to seize opportunities within the thyroid cancer diagnostics market.

Threats

Despite the promising outlook for the thyroid cancer diagnostics market, several threats could hinder its growth. One major threat is the rising costs associated with advanced diagnostic technologies and procedures. As healthcare systems grapple with budget constraints and increasing costs, there may be limitations on the availability and accessibility of cutting-edge diagnostic services, which could negatively impact patient outcomes. Furthermore, the high cost of research and development for new diagnostic tests poses a financial burden on market players, potentially limiting their ability to innovate and compete effectively. Also, the increasing prevalence of false-positive or false-negative results in diagnostic tests can lead to misdiagnosis, resulting in unnecessary complications and undermining patient trust in diagnostic procedures. Addressing these issues will be critical to sustaining market growth and ensuring the continued advancement of thyroid cancer diagnostics.

Restraints in the thyroid cancer diagnostics market primarily stem from regulatory challenges and varying reimbursement policies across different regions. Navigating the complex regulatory landscape can pose significant hurdles for companies looking to introduce new diagnostic technologies or expand their market presence. Moreover, inconsistent reimbursement policies can deter healthcare providers from adopting innovative diagnostic solutions, limiting their availability to patients who may require them. Additionally, the market faces competition from alternative diagnostic methods that may offer similar outcomes at a lower cost, further complicating the landscape. To mitigate these restraining factors, stakeholders must engage in strategic collaborations and advocate for policy changes that support the growth of the thyroid cancer diagnostics industry.

Competitor Outlook

• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Thermo Fisher Scientific
• Genomic Health
• BD (Becton, Dickinson and Company)
• Bio-Rad Laboratories
• Hologic, Inc.
• PerkinElmer, Inc.
• QIAGEN N.V.
• Illumina, Inc.
• Fujifilm Holdings Corporation
• Medtronic
• Philips Healthcare
• GE Healthcare

The thyroid cancer diagnostics market is characterized by a highly competitive landscape, with numerous players striving to establish their presence through innovation and technological advancements. Companies are investing significantly in research and development to introduce new products and improve existing diagnostic services. Strategic collaborations, mergers, and acquisitions are common as companies aim to enhance their market position and expand their offering portfolios. The focus on personalized medicine and the integration of artificial intelligence into diagnostic processes are emerging trends that many companies are leveraging to differentiate themselves from competitors. Furthermore, leading players are enhancing their distribution networks and establishing partnerships with healthcare providers to ensure wider access to their diagnostic services.

Roche Diagnostics, a prominent player in the market, is known for its extensive portfolio of diagnostic solutions, including molecular testing and imaging technologies that are pivotal in thyroid cancer diagnosis. The company invests heavily in R&D to remain at the forefront of innovation and to develop advanced diagnostic tools that enhance patient outcomes. Similarly, Abbott Laboratories continues to expand its presence in the thyroid cancer diagnostics space by introducing cutting-edge blood tests and molecular assays. Its focus on leveraging technology to streamline diagnostic processes has positioned Abbott as a key player in the market.

Siemens Healthineers is another major competitor in the thyroid cancer diagnostics market, offering a wide range of imaging solutions that are crucial for the detection and management of thyroid malignancies. The company’s commitment to advancing imaging technologies enables healthcare professionals to achieve more accurate diagnoses. Furthermore, Thermo Fisher Scientific stands out for its comprehensive approach to molecular testing, providing advanced assays and services tailored to the needs of oncology diagnostics. This commitment to innovation and high-quality products makes Thermo Fisher a significant contributor to the growth of the thyroid cancer diagnostics market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Medtronic
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 QIAGEN N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 GE Healthcare
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Hologic, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Genomic Health
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Illumina, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 PerkinElmer, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Diagnostics
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Philips Healthcare
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Abbott Laboratories
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bio-Rad Laboratories
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Siemens Healthineers
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Thermo Fisher Scientific
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Fujifilm Holdings Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 BD (Becton, Dickinson and Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Thyroid Cancer Diagnostics Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Laboratories
    • 6.1.3 Cancer Research Institutes
    • 6.1.4 Clinics
  • 6.2 Thyroid Cancer Diagnostics Market, By Age Group
    • 6.2.1 Pediatric
    • 6.2.2 Adult
  • 6.3 Thyroid Cancer Diagnostics Market, By Test Type
    • 6.3.1 Biopsy
    • 6.3.2 Blood Tests
    • 6.3.3 Thyroid Ultrasound
    • 6.3.4 Thyroid Scan
    • 6.3.5 Fine Needle Aspiration
  • 6.4 Thyroid Cancer Diagnostics Market, By Technology
    • 6.4.1 Imaging Tests
    • 6.4.2 Molecular Testing
    • 6.4.3 Blood Tests

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Thyroid Cancer Diagnostics Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Thyroid Cancer Diagnostics market is categorized based on

By Test Type

• Biopsy
• Blood Tests
• Thyroid Ultrasound
• Thyroid Scan
• Fine Needle Aspiration

By User

• Hospitals
• Diagnostic Laboratories
• Cancer Research Institutes
• Clinics

By Technology

• Imaging Tests
• Molecular Testing
• Blood Tests

By Age Group

• Pediatric
• Adult

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Thermo Fisher Scientific
• Genomic Health
• BD (Becton, Dickinson and Company)
• Bio-Rad Laboratories
• Hologic, Inc.
• PerkinElmer, Inc.
• QIAGEN N.V.
• Illumina, Inc.
• Fujifilm Holdings Corporation
• Medtronic
• Philips Healthcare
• GE Healthcare